Literature DB >> 17917672

The origin and application of experimental autoimmune encephalomyelitis.

Alan G Baxter1.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a model of the neuroimmune system responding to priming with central nervous system (CNS)-restricted antigens. It is an excellent model of post-vaccinal encephalitis and a useful model of many aspects of multiple sclerosis. EAE has been established in numerous species and is induced by priming with a large number of CNS-derived antigens. As a consequence, the pathogenesis, pathology and clinical signs vary significantly between experimental protocols. As I describe in this Timeline article, the reductionist approach taken in some lines of investigation of EAE resulted in a reliance on results obtained under a narrow range of conditions. Although such studies made important contributions to our molecular understanding of inflammation, T-cell activation, and MHC restriction, they did not advance as effectively our knowledge of the polyantigenic responses that usually occur in CNS immunopathology and autoimmunity.

Entities:  

Mesh:

Year:  2007        PMID: 17917672     DOI: 10.1038/nri2190

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  154 in total

1.  The relevance of animal models in multiple sclerosis research.

Authors:  Aleksandar Denic; Aaron J Johnson; Allan J Bieber; Arthur E Warrington; Moses Rodriguez; Istvan Pirko
Journal:  Pathophysiology       Date:  2011-02

2.  Human endometrial-derived mesenchymal stem cells suppress inflammation in the central nervous system of EAE mice.

Authors:  J P S Peron; T Jazedje; W N Brandão; P M Perin; M Maluf; L P Evangelista; S Halpern; M G Nisenbaum; C E Czeresnia; M Zatz; N O S Câmara; L V Rizzo
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

3.  CNS-derived CCL21 is both sufficient to drive homeostatic CD4+ T cell proliferation and necessary for efficient CD4+ T cell migration into the CNS parenchyma following Toxoplasma gondii infection.

Authors:  Corinne C Ploix; Shahani Noor; Janelle Crane; Kokoechat Masek; Whitney Carter; David D Lo; Emma H Wilson; Monica J Carson
Journal:  Brain Behav Immun       Date:  2010-09-22       Impact factor: 7.217

Review 4.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

Review 5.  Restoring the balance between disease and repair in multiple sclerosis: insights from mouse models.

Authors:  Robert H Miller; Sharyl L Fyffe-Maricich
Journal:  Dis Model Mech       Date:  2010-07-20       Impact factor: 5.758

Review 6.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

7.  Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis.

Authors:  Leslie E Summers deLuca; Natalia B Pikor; Jennifer O'Leary; Georgina Galicia-Rosas; Lesley A Ward; Dustin Defreitas; Trisha M Finlay; Shalina S Ousman; Lucy R Osborne; Jennifer L Gommerman
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

8.  Diffusion tensor imaging identifies aspects of therapeutic estrogen receptor β ligand-induced remyelination in a mouse model of multiple sclerosis.

Authors:  Kelley C Atkinson; Jeong Bin Lee; Jonathan P C Hasselmann; Sung Hoon Kim; Alyson Drew; Joselyn Soto; John A Katzenellenbogen; Neil G Harris; Andre Obenaus; Seema K Tiwari-Woodruff
Journal:  Neurobiol Dis       Date:  2019-06-18       Impact factor: 5.996

9.  Adrenomedullin protects from experimental autoimmune encephalomyelitis at multiple levels.

Authors:  Marta Pedreño; Maria Morell; Gema Robledo; Luciana Souza-Moreira; Irene Forte-Lago; Marta Caro; Francisco O'Valle; Doina Ganea; Elena Gonzalez-Rey
Journal:  Brain Behav Immun       Date:  2013-12-07       Impact factor: 7.217

10.  Functional Effects of Cuprizone-Induced Demyelination in the Presence of the mTOR-Inhibitor Rapamycin.

Authors:  Hana Yamate-Morgan; Kelli Lauderdale; Joshua Horeczko; Urja Merchant; Seema K Tiwari-Woodruff
Journal:  Neuroscience       Date:  2019-01-29       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.